145.05

3.96% -5.98

After Hours: 145.05

Charles River Laboratories International Inc (CRL)

Overview News Price History Option Chain Financials Discussions Forecast

Charles River Laboratories International Inc stock is traded at $145.05, with a volume of 979.21K. It is down -3.96% in the last 24 hours and up +2.89% over the past month. Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Previous Close:

$151.03

Open:

$149.38

24h Volume:

979.21K

Relative Volume:

0.63

Market Cap:

$7.42B

Revenue:

$4.06B

Net Income/Loss:

$413.08M

P/E Ratio:

18.11

EPS:

8.01

Net Cash Flow:

$560.48M

1W Performance:

-3.94%

1M Performance:

+2.89%

6M Performance:

-23.39%

1Y Performance:

-30.40%

1-Day Range:

$143.16

$150.54

1-Week Range:

$143.16

$154.43

52-Week Range:

$91.86

$254.15

Charles River Laboratories International Inc Stock (CRL) Company Profile

Name

Charles River Laboratories International Inc

Sector

Healthcare (1172)

Industry

Diagnostics & Research (54)

Phone

781-222-6000

Address

251 BALLARDVALE ST, WILMINGTON, MA

Employee

20,100

Twitter

@criverlabs

Next Earnings Date

2024-11-06

Latest SEC Filings

CRL's Discussions on Twitter

Compare CRL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRL Charles River Laboratories International Inc	145.05	7.42B	4.06B	413.08M	560.48M	8.01
TMO Thermo Fisher Scientific Inc	390.26	156.49B	42.90B	6.52B	6.72B	17.05
DHR Danaher Corp	195.75	145.01B	23.82B	3.77B	4.90B	5.15
IDXX Idexx Laboratories Inc	520.59	42.30B	3.93B	894.97M	837.70M	10.82
A Agilent Technologies Inc	116.09	34.24B	6.63B	1.17B	1.19B	4.05
IQV Iqvia Holdings Inc	154.10	27.64B	15.50B	1.33B	2.16B	7.34

Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-23-25	Upgrade	Redburn Atlantic	Neutral → Buy
May-14-25	Upgrade	TD Cowen	Hold → Buy
May-08-25	Upgrade	Evercore ISI	In-line → Outperform
Mar-21-25	Downgrade	Goldman	Buy → Neutral
Mar-04-25	Upgrade	Citigroup	Sell → Neutral
Mar-03-25	Upgrade	Redburn Atlantic	Sell → Neutral
Jan-22-25	Downgrade	William Blair	Outperform → Mkt Perform
Jan-17-25	Downgrade	UBS	Buy → Neutral
Nov-18-24	Downgrade	CLSA	Hold → Underperform
Nov-07-24	Upgrade	CLSA	Underperform → Hold
Oct-23-24	Initiated	CLSA	Underperform
Oct-14-24	Initiated	Redburn Atlantic	Sell
Oct-07-24	Downgrade	Evercore ISI	Outperform → In-line
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral
Oct-01-24	Downgrade	Citigroup	Neutral → Sell
Aug-08-24	Downgrade	JP Morgan	Overweight → Neutral
Aug-08-24	Downgrade	Robert W. Baird	Outperform → Neutral
Jun-28-24	Downgrade	Argus	Buy → Hold
Jun-07-24	Initiated	Mizuho	Neutral
Jun-06-24	Initiated	Goldman	Buy
Feb-15-24	Downgrade	Guggenheim	Buy → Neutral
Sep-13-23	Initiated	TD Cowen	Market Perform
Jul-10-23	Downgrade	Citigroup	Buy → Neutral
Feb-23-23	Upgrade	Guggenheim	Neutral → Buy
Jan-12-23	Downgrade	Jefferies	Buy → Hold
Sep-30-22	Upgrade	Jefferies	Hold → Buy
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-04-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-24-22	Initiated	Guggenheim	Neutral
Apr-25-22	Downgrade	Jefferies	Buy → Hold
Apr-07-22	Initiated	Stephens	Overweight
Feb-17-22	Reiterated	BofA Securities	Buy
Feb-17-22	Upgrade	Citigroup	Neutral → Buy
Feb-17-22	Reiterated	Deutsche Bank	Buy
Feb-17-22	Reiterated	Morgan Stanley	Overweight
Feb-17-22	Reiterated	UBS	Buy
Aug-05-21	Resumed	Credit Suisse	Neutral
Dec-16-20	Downgrade	Citigroup	Buy → Neutral
Sep-10-20	Upgrade	Jefferies	Hold → Buy
Jul-01-20	Upgrade	BofA Securities	Neutral → Buy
May-13-20	Upgrade	UBS	Neutral → Buy
Apr-21-20	Downgrade	Jefferies	Buy → Hold
Mar-27-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-02-20	Initiated	Deutsche Bank	Buy
Feb-18-20	Upgrade	Wolfe Research	Peer Perform → Outperform
Jan-10-20	Upgrade	Goldman	Neutral → Buy
Jan-08-20	Initiated	Wells Fargo	Overweight
Jan-07-20	Initiated	Citigroup	Buy
Oct-18-19	Downgrade	BofA/Merrill	Buy → Neutral
Jun-10-19	Initiated	SVB Leerink	Outperform
Apr-30-19	Resumed	Evercore ISI	Outperform
Dec-14-18	Initiated	Deutsche Bank	Buy
Oct-09-18	Initiated	UBS	Neutral
Aug-23-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-17-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-15-18	Upgrade	KeyBanc Capital Mkts	Sector Weight → Overweight
Feb-14-18	Upgrade	SunTrust	Hold → Buy

View All

Charles River Laboratories International Inc Stock (CRL) Latest News

Jun 17, 2025

Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Jun 17, 2025

Jun 16, 2025

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment | CRL Stock News - GuruFocus

Jun 16, 2025

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment - Business Wire

Jun 16, 2025

Charles River Laboratories credit outlook lowered to stable at S&P on weak 2025 guidance - MSN

Jun 13, 2025

Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN

Jun 13, 2025

Jun 12, 2025

Charles River surges after Q1 beat, guidance raise - MSN

Jun 12, 2025

FDA’s Intent To Phase Out Animal Testing Requirement Weighs Down Charles River Stock: Retail’s Disheartened - MSN

Jun 12, 2025

Jun 11, 2025

Insiders At Charles River Laboratories International Sold US$2.8m In Stock, Alluding To Potential Weakness - simplywall.st

Jun 11, 2025

Rhumbline Advisers Increases Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat

Jun 11, 2025

Jun 09, 2025

Transcript : Charles River Laboratories International, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - marketscreener.com

Jun 09, 2025

Polen U.S SMID Company Growth Strategy Sold Charles River Laboratories International (CRL) for More Attractive Opportunities - Insider Monkey

Jun 09, 2025

Jun 06, 2025

Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN

Jun 06, 2025

Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report? - Yahoo Finance

Jun 06, 2025

Jun 05, 2025

Regulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - GlobeNewswire Inc.

Jun 05, 2025

Jun 04, 2025

William Blair Remains a Hold on Charles River Labs (CRL) - The Globe and Mail

Jun 04, 2025

Charles River at Jefferies Conference: Strategic Moves Amid Challenges By Investing.com - Investing.com Canada

Jun 04, 2025

Transcript : Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 10 - marketscreener.com

Jun 04, 2025

Charles River Laboratories To Present At Jefferies Global Conference; Webcast At 10:30 AM ET - Nasdaq

Jun 04, 2025

Cell Banking Outsourcing Market To Witness Substantial Growth, - openPR.com

Jun 04, 2025

Jun 03, 2025

Charles River Stock May Gain From Extended CHDI Research Deal on HD - MSN

Jun 03, 2025